89 results on '"Gil-Martínez M"'
Search Results
2. Intercultural Interaction of Smart Nation: Trends, Problems and Decisions
- Author
-
Vorontsova, Yu. V., primary, Arakelyan, A. M., additional, and Gil Martínez, M. A., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Clinical features, management and outcomes of patients with sterile endophthalmitis associated with intravitreal injection of antivascular endothelial growth factor
- Author
-
Gil-Martínez, M., Rodríguez-Cid, M.J., Fenández-Rodriguez, M.I., Blanco-Teijero, M.J., Abraldes, M.J., Bandín Vilar, E., Zarra-Ferro, I., González-Barcia, M., Gómez-Ulla, F., and Fernández-Ferreiro, A.
- Published
- 2020
- Full Text
- View/download PDF
4. Características clínicas, manejo y resultados de los pacientes con endoftalmitis estéril asociados con la inyección intravítrea de factores de crecimiento endotelial antivascular
- Author
-
Gil-Martínez, M., Rodríguez-Cid, M.J., Fenández-Rodríguez, M.I., Blanco-Teijero, M.J., Abraldes, M.J., Bandín Vilar, E., Zarra-Ferro, I., González-Barcia, M., Gómez-Ulla, F., and Fernández-Ferreiro, A.
- Published
- 2020
- Full Text
- View/download PDF
5. Long‐term immune response accompanies clinical outcomes in severe asthmatics treated with anti‐IL‐5/IL‐5R biologics
- Author
-
Lorente‐Sorolla, C., primary, Bernaola, J., additional, Sánchez‐Mellado, D., additional, Gil‐Martínez, M., additional, Naharro‐González, S., additional, Betancor, D., additional, Fernández‐Nieto, M., additional, Pinillos‐Robles, E. J., additional, Santillán Coello, J. M., additional, Villacampa‐Aubá, J. M., additional, Rodríguez‐Nieto, M. J., additional, Sastre, J., additional, Valverde‐Monge, M., additional, Rodrigo‐Muñoz, J. M., additional, and del Pozo, V., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Exploring the possibilities of transhumanistic risk management
- Author
-
Vorontsova, Yu. V., primary and Gil Martínez, M. A., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Serum microRNAs Catalog Asthma Patients by Phenotype
- Author
-
Gil-Martínez, M, primary, Rodrigo-Muñoz, JM, additional, Sastre, B, additional, Cañas, JA, additional, García-Latorre, R, additional, Redondo, N, additional, de la Fuente, L, additional, Mínguez, P, additional, Mahíllo-Fernández, I, additional, Sastre, J, additional, Quirce, S, additional, Caballero, ML, additional, Olaguibel, JM, additional, and del Pozo, V, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Improvements in ATAD using quantitative feedback control and nonlinear generator of optimal operating points
- Author
-
Nájera, S., Zambrano, J.A., and Gil-Martínez, M.
- Published
- 2013
- Full Text
- View/download PDF
9. 6ER-027 Blood cytokine evaluation in patients with intravitreal ranibizumab for neovascular age-related macular degeneration
- Author
-
García-Quintanilla, L, primary, Almuiña-Varela, P, additional, Mondelo-García, C, additional, Gil-Martínez, M, additional, Abraldes, MJ, additional, Rodríguez-Cid, MJ, additional, Fernández-Rodríguez, MI, additional, Castro-Balado, A, additional, Zarra-Ferro, I, additional, and Fernández-Ferreiro, A, additional
- Published
- 2022
- Full Text
- View/download PDF
10. Benchmark de control de la orientación de un multirrotor en una estructura de rotación con tres grados de libertad
- Author
-
Rico-Azagra, J., primary, Gil-Martínez, M., additional, Rico, R., additional, Nájera, S., additional, and Elvira, C., additional
- Published
- 2021
- Full Text
- View/download PDF
11. Eosinophil Response Against Classical and Emerging Respiratory Viruses: COVID-19
- Author
-
Rodrigo-Muñoz, JM, primary, Sastre, B, additional, Cañas, JA, additional, Gil-Martínez, M, additional, Redondo, N, additional, and del Pozo, V, additional
- Published
- 2021
- Full Text
- View/download PDF
12. Research of the peculiarities of enterpises՚ work organization in the intercultural space
- Author
-
Gil Martínez, M. A., primary and Vorontsova, Yu. V., additional
- Published
- 2021
- Full Text
- View/download PDF
13. CONTROL ENGINEERING LEARNING USING A SOFTWARE TOOL FOR A LAB MOTOR
- Author
-
Gil-Martínez, M. and Martín, R.
- Published
- 2006
- Full Text
- View/download PDF
14. [Home and Ambulatory Artificial Nutrition (NADYA) Report. Home Parenteral Nutrition in Spain, 2017]
- Author
-
Wanden-Berghe Lozano, Carmina, Pereira Cunill, José Luis, Cuerda Compes, Cristina, Ramos Boluda, Esther, Maiz Jiménez, María Irene, Gómez Candela, Carmen, Virgili Casas, Nuria, Burgos Peláez, Rosa, Pérez de la Cruz, Antonio, Penacho Lázaro, M ª Ángeles, Sánchez Martos, Eva Ángeles, De Luis Román, Daniel Antonio, Martínez Faedo, Ceferino, Martín Fontalba, María de Los Ángeles, Álvarez Hernández, Julia, Matía Martín, Pilar, Díaz Guardiola, Patricia, Carabaña Pérez, Fátima, Sanz París, Alejandro, Garde Orbaiz, Carmen, Sánchez-Vilar Burdiel, Olga, Martín Folgueras, Tomás, Martín Palmero, M ª Ángela, Luengo Pérez, Luis Miguel, Zugasti Murillo, Ana, Martínez Costa, Cecilia, Suárez Llanos, José Pablo, Tejera Pérez, Cristina, Irles Rocamora, José Antonio, Arraiza Irigoyen, Carmen, García Delgado, Yaiza, Campos Martín, Cristina, Ponce González, Miguel Ángel, Mauri Roca, Silvia, García Zafra, M ª Victoria, Morán López, Jesús M, Molina Baeza, Begoña, Gonzalo Marín, Montserrat, Joaquín Ortiz, Clara, Pintor de la Maza, Begoña, Gil Martínez, M ª Carmen, Carrera Santaliestra, María José, Forga Visa, M ª Del Talló, Apezetxea Celaya, Antxón, Sánchez Sánchez, Rebeca, and Urgeles Planella, Juan Ramón
- Subjects
Adult ,Male ,Short Bowel Syndrome ,Spain ,Neoplasms ,Palliative Care ,Humans ,Female ,Hirschsprung Disease ,Registries ,Child ,Parenteral Nutrition, Home - Abstract
to communicate HPN data obtained from the HPN registry of the NADYA-SENPE group (www.nadya-senpe.com) for the year 2017.descriptive analysis of the data collected from adult and pediatric patients with HPN in the NADYA-SENPE group registry from January 1st, 2017 to December 31st, 2017.there were 308 patients from 45 Spanish hospitals (54.5% women), 38 children and 270 adults, with 3,012 episodes, which represent a prevalence rate of 6.61 patients/million inhabitants/year 2017. The most frequent diagnosis in adults was "palliative cancer" (25.6%), followed by "others". In children, it was Hirschsprung's disease with six cases (15.8%). The first indication was short bowel syndrome in both children (55.3%) and adults (33.7%). The most frequently used type of catheter was tunneled in both children (73.4%) and adults (38.2%). Ending 81 episodes, the most frequent cause was death (62.9%) and transition to oral feeding (34.7%).the progressive increase of collaborating centers and professionals in the registry of patients receiving NPD is maintained. The main indications of HPN and the motive for ending have remained stable.OBJETIVO: comunicar los datos de nutrición parenteral domiciliaria (NPD) obtenidos del registro del grupo NADYA-SENPE (www.nadya-senpe. com) del año 2017. MATERIAL Y MÉTODOS: análisis descriptivo de los datos recogidos de pacientes adultos y pediátricos con NPD en el registro NADYA-SENPE desde el 1 de enero al 31 de diciembre de 2017. RESULTADOS: se registraron 308 pacientes (54,5% mujeres), 38 niños y 270 adultos, procedentes de 45 hospitales españoles, en total 312 episodios, lo que representa una tasa de prevalencia de 6,61 pacientes/millón de habitantes/año 2017. El diagnóstico más frecuente en adultos fue “oncológico paliativo” (25,6%), seguido de “otros”. En niños fue la enfermedad de Hirschsprung, con seis casos (15,8%). El primer motivo de indicación fue síndrome de intestino corto tanto en niños (55,3%) como en adultos (33,7%). El tipo de catéter más utilizado fue el tunelizado tanto en niños (74,3%) como en adultos (38,2%). Finalizaron 81 episodios; la causa más frecuente fue el fallecimiento (62,9%) y que pasaron a vía oral (34,7%). CONCLUSIONES: se mantiene el incremento progresivo de centros y profesionales colaboradores en el registro de pacientes que reciben NPD. Las principales indicaciones de NPD y de motivo de finalización se mantienen estables.
- Published
- 2018
15. Plant Uncertainty Contribution to QFT Tracking Control Design
- Author
-
Gil-Martínez, M. and García-Sanz, M.
- Published
- 2003
- Full Text
- View/download PDF
16. ROBUST SPECIFICATION INFLUENCE ON FEEDBACK CONTROL STRATEGIES
- Author
-
Gil-Martínez, M. and García-Sanz, M.
- Published
- 2002
- Full Text
- View/download PDF
17. Evaluation of amendment addition and tree planting as measures to remediate contaminated soils: The Guadiamar case study (SW Spain)
- Author
-
Madejón, P., primary, Domínguez, M.T., additional, Gil-Martínez, M., additional, Navarro-Fernández, C.M., additional, Montiel-Rozas, M.M., additional, Madejón, E., additional, Murillo, J.M., additional, Cabrera, F., additional, and Marañón, T., additional
- Published
- 2018
- Full Text
- View/download PDF
18. Current use of Antifungal Eye Drops and How to Improve Therapeutic Aspects in Keratomycosis
- Author
-
Victoria Díaz Tome, Miguel González-Barcia, María Jesús Lamas, FJ Otero-Espinar, Anxo Fern, ez-Ferreiro, Gil Martínez M, and Blanco Méndez J
- Subjects
Voriconazole ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Eye drop ,Retrospective cohort study ,Pharmacy ,Omics ,medicine.disease ,Dermatology ,Surgery ,Natamycin ,medicine ,Fungal keratitis ,business ,Fluconazole ,medicine.drug - Abstract
Background: Fungal keratitis is a disease that has a low prevalence and poor outcome because of its minimal therapeutic spectrum. Objective: The purpose of the current study is to provide an overview of the use of antifungal topical eye drops in a third level hospital and to highlight possible improvements that can optimize their therapeutic use. Methods: Fungal keratitis cases treated in the Ophthalmology Department of a Tertiary hospital were reviewed in a four-year retrospective study. Results: For four years, 24 patients received an antifungal eye drop treatment for fungal keratitis: 20% were treated with topical fluconazole and 80% were treated with topical voriconazole (79% in monotherapy and 21% in conjunction with topical natamycin). In most cases, fungal growth was been detected and susceptibility was rarely reported, facilitating the realization of directed treatment towards the most frequently isolated fungi (Fusarium, Candida, Paecilomyces). Conclusion: In a disease with low prevalence and complicated management, we have detected improvement in the three involved departments: ophthalmology, pharmacy and microbiology.
- Published
- 2016
19. QFT bounds for robust stability specifications defined on the open-loop function
- Author
-
Rico-Azagra, J., primary, Gil-Martínez, M., additional, Rico, R., additional, and Maisterra, P., additional
- Published
- 2017
- Full Text
- View/download PDF
20. Análisis de la toxicidad ocular de los colirios de voriconazol y fluconazol con HET-CAM
- Author
-
Fernández-Ferreiro, A., González Barcia, M., Gil Martínez, M., Blanco Mendez, J., Lamas Díaz, M. J., and Otero Espinar, F. J.
- Subjects
Colirios ,Ocular toxicity ,Fluconazol ,HET-CAM ,Eye drops ,Toxicidad ocular ,Voriconazol ,Voriconazole ,Fluconazole - Abstract
Objetivo: El objetivo del estudio es aportar información toxicológica mediante el ensayo HET-CAM, de los colirios de Fluconazol y Voriconazol elaborados de manera habitual en los Servicios de Farmacia para el tratamiento de las queratitis fúngicas. Métodos: Estudio experimental en el que se ensaya la potencial toxicidad ocular del colirio de voriconazol 10 mg/ml y fluconazol 2 mg/ml mediante el método Hen s Egg Test-Chorioallantoic Membrane (HET-CAM). Los resultados se fundamentan en la observación de los posibles procesos dañinos que pudiesen ocurrir en los vasos sanguíneos de la membrana corioalantoidea del embrión de pollo durante un tiempo de contacto de 300 segundos, calculándose posteriormente el índice de irritación (IS, Irritation Score). Resultados y conclusiones: Se obtienen IS nulos para ambas muestras, no mostrando por tanto indicios de irritación aguda apreciables, considerándose por tanto aptos para su utilización desde el punto de vista toxicológico. Purpose: The objective of the study is to provide toxicological information through the HET-CAM test of Fluconazole and Voriconazole eye drops prepared commonly in Pharmacy Services for the treatment of fungal keratitis. Method: Experimental Study. The ocular toxicity of topical voriconazole 10 mg/ml and fluconazole 2 mg/ml were evaluated by the hen's egg test (HET) on the chorioallantoic membrane (CAM). The effects on blood vessels were based on its behavior during 300 seconds and processes that may occur at each time, then we calculated the irritation index (is, irritation score). Results and conclusions: Both eye drops, voriconazol and fluconazole have been proven to be safe, since the IS that we obtained was zero for both samples and did not present significant signs of irritation. Therefore, these eyedrops are considered suitable for ocular use from a toxicological point of view.
- Published
- 2014
21. Análisis de la toxicidad ocular de los colirios de voriconazol y fluconazol con HET-CAM
- Author
-
Fernández-Ferreiro,A., González Barcia,M., Gil Martínez,M., Blanco Mendez,J., Lamas Díaz,M. J., and Otero Espinar,F. J.
- Subjects
Colirios ,Fluconazol ,HET-CAM ,Toxicidad ocular ,Voriconazol - Abstract
Objetivo: El objetivo del estudio es aportar información toxicológica mediante el ensayo HET-CAM, de los colirios de Fluconazol y Voriconazol elaborados de manera habitual en los Servicios de Farmacia para el tratamiento de las queratitis fúngicas. Métodos: Estudio experimental en el que se ensaya la potencial toxicidad ocular del colirio de voriconazol 10 mg/ml y fluconazol 2 mg/ml mediante el método Hen s Egg Test-Chorioallantoic Membrane (HET-CAM). Los resultados se fundamentan en la observación de los posibles procesos dañinos que pudiesen ocurrir en los vasos sanguíneos de la membrana corioalantoidea del embrión de pollo durante un tiempo de contacto de 300 segundos, calculándose posteriormente el índice de irritación (IS, Irritation Score). Resultados y conclusiones: Se obtienen IS nulos para ambas muestras, no mostrando por tanto indicios de irritación aguda apreciables, considerándose por tanto aptos para su utilización desde el punto de vista toxicológico.
- Published
- 2014
22. Nutrición Parenteral Domiciliaria en España 2011 y 2012: informe del grupo de nutrición artificial domiciliaria y ambulatoria NADYA
- Author
-
Wanden-Berghe, Carmina, Moreno Villarés, J M, Cuerda Compés, C, Carrero, C, Burgos, R, Gómez Candela, C, Virgili Casas, N, Martínez Faedo, C, Alvarez, J, Sánchez Martos, E A, Matía Martín, P, Zugasti, A, Olveira, G, Luengo, L M, Campos Martín, C, Martín Folgueras, T, Penacho Lázaro, M A, Pereira, J L, Garde Orbaiz, C, Pérez de la Cruz, A, Apezetxea, A, Sánchez-Vilar, O, Gil Martínez, M C, Martínez Costa, C, Luis, D De, Laborda, L, Joaquin Ortiz, C, Suárez Llanos, J P, Leyes García, P, Ponce González, M A, and [Wanden-Berghe,C] Universidad CEU Cardenal Herrera, Elche. Hospital General de Alicante. [Moreno Villarés,JM] Hospital 12 De Octubre, Madrid. [Cuerda Compés,C] Hospital Gregorio Marañón, Madrid. [Carrero,C] Hospital Ramón y Cajal, Madrid. [Burgos,R] Hospital Vall d'Hebrón, Barcelona. [Gómez Candela,C] Hospital La Paz, Madrid. [Virgili Casas,N] Hospital Bellvitge, Barcelona. [Martínez Faedo,C] Hospital Central de Asturias. [Alvarez,J] Hospital Príncipe de Asturias, Madrid. [Sánchez Martos,EA] Hospital Parc Taulí, Barcelona. [Matía Martín,P] Hospital Clínico San Carlos, Madrid. [Zugasti,A] Hospital Virgen del Camino, Pamplona. [Olveira, G] Hospital Carlos Haya, Málaga. [Luengo,LM] Hospital Infanta Cristina, Badajoz. [Campos Martín,C] Hospital Virgen Macarena, Sevilla. [Martín Folgueras,T] Complejo Hospitalario de Canarias, Tenerife. [Penacho Lázaro,MA] Hospital El Bierzo, Ponferrada. [Pereira,JL] Hospital Virgen del Rocío, Sevilla. [Garde Orbaiz,C] Hospital Donostia, San Sebastian. [Pérez de la Cruz,A] Hospital Virgen de las Nieves, Granada. [Apezetxea,A] Hospital Basurto, Bilbao. [Sánchez-Vilar,O] no identificado [Gil Martínez,MC] Hospital Gómez Ulla,Madrid. [Martínez Costa,C] Hospital Clínico, Valencia. [De Luis,D] Hospital Río Hortega, Valladolid. [Laborda,L] Hospital Cruces, Bilbao. [Joaquin Ortiz,C] Hospital Germans Trias i Pujol, Barcelona. [Suárez Llanos,JP] Hospital La Candelaria, Tenerife. [Leyes García,P] Hospital Clinic, Barcelona. [Ponce González,MA] Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España.
- Subjects
Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings] ,Home parenteral nutrition ,Nutrición parenteral domiciliaria ,Nutrición parenteral ,Parenteral nutrition ,lcsh:Nutritional diseases. Deficiency diseases ,Health Care::Health Care Facilities, Manpower, and Services::Health Services::Community Health Services::Home Care Services::Parenteral Nutrition, Home [Medical Subject Headings] ,Registros ,Registries ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries [Medical Subject Headings] ,Disciplines and Occupations::Health Occupations::Medicine::Public Health::Epidemiology [Medical Subject Headings] ,Chemicals and Drugs::Pharmaceutical Preparations::Solutions::Pharmaceutical Solutions::Parenteral Nutrition Solutions [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Decision Support Techniques::Data Interpretation, Statistical [Medical Subject Headings] ,lcsh:RC620-627 - Abstract
OBJETIVE: To report the data of the Home Parenteral Nutrition (HPN) registry of the NADYA-SENPE working group for the years 2011 and 2012. METHODOLOGY: We compiled the data from the on-line registry introduced by reviewers of NADYA group responsible for monitoring of NPD introduced by since January 1, 2011 to december 31, 2012. Included fields were: age, sex, diagnosis and reason for HPN, access path, complications, beginning and end dates, complementary oral or enteral nutrition, activity level, autonomy degree, product and fungible material supply, withdrawal reason and intestinal transplant indication. RESULTS: Year 2010: 184 patients from 29 hospitals , representing a rate of 3.98 patients/million inhabitants/ year 2011, with 186 episodes were recorded NPD . During 2012, 203 patients from 29 hospitals , representing a rate of 4.39 patients/million inhabitants/year 2012 , a total of 211 episodes were recorded NPD . CONCLUSIONS: We observe an increase in registered patients with respect to previous years.Neoplasia remains as the main pathology since 2003. Although NADYA is consolidated registry and has been indispensable source of information relevant to the understanding of the progress of Home Artificial Nutrition in our country, there is ample room for improvement. Especially that refers to the registration of pediatric patients and the registration of complications. Yes Objetivo: Comunicar los datos del registro de Nutrición Parenteral Domiciliaria (NPD) del grupo de trabajo NADYA-SENPE de los años 2011 y 2012. Material y métodos: Recopilación de los datos del registro “on-line” introducidos por los colaboradores del grupo NADYA responsables del seguimiento de la NPD desde el 1 de enero de 2011 al 31 de diciembre de 2012 dividido por años naturales. Resultados: Año 2010: Se registraron 184 pacientes, procedentes de 29 hospitales, lo que representa una tasa de 3,98 pacientes/millón habitantes/año 2011, con 186 episodios de NPD. Durante el año 2012 se registraron 203 pacientes, procedentes de 29 hospitales, lo que representa una tasa de 4,39 pacientes/millón habitantes/año 2012, con un total de 211 episodios de NPD. Conclusiones: Se observa un aumento progresivo de los pacientes registrados respecto a años anteriores. El principal grupo patológico sigue siendo oncológico ocupando el primer lugar desde 2003. Aunque el registro NADYA es un registro consolidado y ha sido y es fuente imprescindible de información relevante para el conocimiento de los avances de la Nutrición Artificial Domiciliaria en nuestro país, queda un amplio margen para la mejora. En especial lo que hace referencia al registro de pacientes pediátricos y al registro de las complicaciones.
- Published
- 2014
23. QFT bounds for robust stability specifications defined on the open‐loop function.
- Author
-
Rico‐Azagra, J., Gil‐Martínez, M., Rico, R., and Maisterra, P.
- Subjects
- *
QUANTITATIVE feedback theory , *ROBUST stability analysis , *BANDWIDTHS , *ALGORITHMS , *DRONE aircraft - Abstract
Summary: In the framework of quantitative feedback theory, this paper develops a new method to compute robust stability bounds. This is of special interest when stability is defined directly on the open‐loop function. Thus, ignorance of the plant gain and phase shift can be specifically and independently considered. Furthermore, upper and lower stability margins for both gain and phase can be chosen. However, classical quantitative feedback theory stability specifications are defined as constraining the peak magnitude of closed‐loop functions, which lack the said flexibility. Once the upper tolerance has been defined, all stability margins are determined. Moreover, confining the most restrictive stability margin may result in other excessive margins. However, the stability bounds of the new approach guard just the required distance from the open‐loop frequency response to the critical point. This allows maximization of the available feedback in the functional bandwidth and minimization of the cost of feedback beyond the crossover frequency, provided that the open‐loop frequency response is shaped to closely follow the stability bounds. It should be noted that the new bound computation algorithm performs few and simple arithmetic operations. This makes it far more efficient than traditional methods. The flight altitude control of an unmanned aerial vehicle is proposed as a practical example to show the new method's potential benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. DI-023 Effect of different antifugal eye drops on human corneal cells in vitro
- Author
-
Fernández-Ferreiro, A, primary, Santiago-Varela, M, additional, Gil-Martínez, M, additional, Pardo-Perez, M, additional, González-Barcia, M, additional, Piñeiro-Ces, A, additional, Blanco-Mendez, J, additional, Lamas Díaz, MJ, additional, and Otero-Espinar, F, additional
- Published
- 2015
- Full Text
- View/download PDF
25. ATAD control goals through the analysis of process variables and evaluation of quality, production and cost
- Author
-
Nájera, S., primary, Gil-Martínez, M., additional, and Zambrano, J. A., additional
- Published
- 2015
- Full Text
- View/download PDF
26. Simultaneous meeting of robust control specifications in QFT
- Author
-
Gil-Martínez, M. and García-Sanz, M.
- Subjects
Robust control ,Uncertain systems ,Quantitative feedback theory (QFT) - Abstract
Simultaneous meeting of different-nature feedback control specifications requires special attention, particularly in the presence of uncertainties. This paper introduces some ideas to obtain a feasible set of QFT bounds, analysing the compatibility of the desired control specifications and the model uncertainty. It studies general robust feedback requirements and their mapping on QFT bounds through quadratic inequalities. Analysing them, it is possible to infer the bound typology with dependence on the model of each particular specification and the uncertainty size. Two bound typologies (amongst three categories: upper, outer and lower bounds) are possible for each type of control objective. On this basis, some general hints are established to guarantee compatible bounds at each frequency, before designing the controller. Copyright © 2003 John Wiley & Sons, Ltd.
- Published
- 2003
27. MON-PP105: Home Parenteral Nutrition - National Record 2014
- Author
-
Wanden-Berghe, C., Cuerda Compés, C., Moreno Villares, J., Perez de la Cruz, A., Burgos, R., Gómez Candela, C., Virgili Casas, N., Penacho Lázaro, M., Martinez Faedo, C., Gonzalo Marín, M., Garde Orbaiz, C., Campos Martín, C., Sanchez Martos, E., Sanz Paris, A., García Luna, P., Matía Martín, P., Mauri, S., Hernández Nieto, M., Alvarez, J., Carabaña Perez, F., García Zafra, M., Martinez Costa, C., De Luis Román, D., Suarez Llanos, J., Zugasti, A., Apezetxea, A., Urgelles Planella, J., Laborda Gonzalez, L., Sónchez-Vilar Burdiel, O., Joaquín Ortiz, C., Gil Martínez, M., Calleja, A., Leyes Garcia, P., Ponce Gonzalez, M., Del Olmo García, M., Luengo, L., and on behalf of NADYA-SENPE Group
- Published
- 2015
- Full Text
- View/download PDF
28. Simultaneous meeting of robust control specifications in QFT
- Author
-
Gil‐Martínez, M., primary and García‐Sanz, M., additional
- Published
- 2003
- Full Text
- View/download PDF
29. Use of fortified antibiotic eye drops on eye infections
- Author
-
Anxo Fernández Ferreiro, González Barcia, M., Gil Martínez, M., Alba Domínguez, J., Otero Espinar, F. J., Blanco Méndez, J., Harriet Romero, R. E., and Lamas Díaz, M. J.
30. XLIII Jornadas de Automática: libro de actas: 7, 8 y 9 de septiembre de 2022, Logroño (La Rioja)
- Author
-
Comité Español de Automática, Universidad de La Rioja, Balaguer, Carlos, Andújar-Márquez, José Manuel, Costa-Castelló, R., Ocampo-Martínez, C., Fernández-Lozano, Juan Jesús, Santos, M., Simó, José, Gil-Martínez, M., Calvo-Rolle, José Luis, Marín, Raúl, Rocón, Eduardo, Estévez, Elisabet, Cabrera, Pedro, Muñoz de la Peña, David, Guzmán, J.L., Pitarch, José Luis, Reinoso, Óscar, Déniz, Óscar, Jiménez, Emilio, and Loureiro, Vanesa
- Subjects
Bioingeniería ,Educación en Automática ,Jornadas de Automática ,Automática ,Automar ,Proceedings ,Computadores y control ,Control inteligente ,Simulación y optimización ,Ingeniería de control ,Modelado ,Visión por computador ,Robótica - Abstract
[Resumen] Las Jornadas de Automática (JA) son el evento más importante del Comité Español de Automática (CEA), entidad científico-técnica con más de cincuenta años de vida y destinada a la difusión e implantación de la Automática en la sociedad. Este año se celebra la cuadragésima tercera edición de las JA, que constituyen el punto de encuentro de la comunidad de Automática de nuestro país. La presente edición permitirá dar visibilidad a los nuevos retos y resultados del ámbito, y su uso en un gran número de aplicaciones, entre otras, las energías renovables, la bioingeniería o la robótica asistencial. Además de la componente científica, que se ve reflejada en este libro de actas, las JA son un punto de encuentro de las diferentes generaciones de profesores, investigadores y profesionales, incluyendo la componente social que es de vital importancia. Esta edición 2022 de las JA se celebra en Logroño, capital de La Rioja, región mundialmente conocida por la calidad de sus vinos de Denominación de Origen y que ha asumido el desafío de poder ganar competitividad a través de la transformación verde y digital. Pero también por ser la cuna del castellano e impulsar el Valle de la Lengua con la ayuda de las nuevas tecnologías, entre ellas la Automática Inteligente. Los organizadores de estas JA, pertenecientes al Área de Ingeniería de Sistemas y Automática del Departamento de Ingeniería Eléctrica de la Universidad de La Rioja (UR), constituyen un pilar fundamental en el apoyo a la región para el estudio, implementación y difusión de estos retos. Esta edición, la primera en formato íntegramente presencial después de la pandemia de la covid-19, cuenta con más de 200 asistentes y se celebra a caballo entre el Edificio Politécnico de la Escuela Técnica Superior de Ingeniería Industrial y el Monasterio de Yuso situado en San Millán de la Cogolla, dos marcos excepcionales para la realización de las JA. Como parte del programa científico, dos sesiones plenarias harán hincapié, respectivamente, sobre soluciones de control para afrontar los nuevos retos energéticos, y sobre la calidad de los datos para una inteligencia artificial (IA) imparcial y confiable. También, dos mesas redondas debatirán aplicaciones de la IA y la implantación de la tecnología digital en la actividad profesional. Adicionalmente, destacaremos dos clases magistrales alineadas con tecnología de última generación que serán impartidas por profesionales de la empresa. Las JA también van a albergar dos competiciones: CEABOT, con robots humanoides, y el Concurso de Ingeniería de Control, enfocado a UAVs. A todas estas actividades hay que añadir las reuniones de los grupos temáticos de CEA, las exhibiciones de pósteres con las comunicaciones presentadas a las JA y los expositores de las empresas. Por último, durante el evento se va a proceder a la entrega del “Premio Nacional de Automática” (edición 2022) y del “Premio CEA al Talento Femenino en Automática”, patrocinado por el Gobierno de La Rioja (en su primera edición), además de diversos galardones enmarcados dentro de las actividades de los grupos temáticos de CEA. Las actas de las XLIII Jornadas de Automática están formadas por un total de 143 comunicaciones, organizadas en torno a los nueve Grupos Temáticos y a las dos Líneas Estratégicas de CEA. Los trabajos seleccionados han sido sometidos a un proceso de revisión por pares.
- Full Text
- View/download PDF
31. Analysis of Differentially Expressed MicroRNAs in Serum and Lung Tissues from Individuals with Severe Asthma Treated with Oral Glucocorticoids
- Author
-
Gil-Martínez, Marta, Lorente-Sorolla, Clara, Rodrigo-Muñoz, José M., Lendínez, Miguel Ángel, Núñez-Moreno, Gonzalo, de la Fuente, Lorena, Mínguez, Pablo, Mahíllo-Fernández, Ignacio, Sastre, Joaquin, Valverde-Monge, Marcela, Quirce, Santiago, Caballero, María L., González-Barcala, Francisco J., Arismendi, Ebymar, Bobolea, Irina, Valero, Antonio, Muñoz Gall, Xavier, Cruz, María Jesús, Martínez Rivera, Carlos, Plaza, Vicente, Olaguibel, José M., del Pozo, Victoria, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Gil-Martínez M, Rodrigo-Muñoz JM] Immunoallergy Laboratory, Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain. CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Lorente-Sorolla C, Lendínez MÁ] Immunoallergy Laboratory, Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain. [Núñez-Moreno G] Department of Genetics, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain. Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Bioinformatics Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain. [de la Fuente L] Department of Genetics, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain. [Muñoz X, Cruz MJ] CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs [CHEMICALS AND DRUGS] ,Asma - Tractament ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Mirnas ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Catalysis ,acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas::glucocorticoides [COMPUESTOS QUÍMICOS Y DROGAS] ,Inorganic Chemistry ,biomarker ,oral corticosteroids ,miRNAs ,individuals with severe asthma ,Oral corticosteroids ,Other subheadings::/therapeutic use [Other subheadings] ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy ,MicroARN ,Individuals with severe asthma ,Otros calificadores::/uso terapéutico [Otros calificadores] ,Organic Chemistry ,General Medicine ,Biomarker ,Respiratory Tract Diseases::Bronchial Diseases::Asthma [DISEASES] ,Computer Science Applications ,enfermedades respiratorias::enfermedades bronquiales::asma [ENFERMEDADES] ,Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Glucocorticoids [CHEMICALS AND DRUGS] ,nucleótidos y nucleósidos de ácidos nucleicos::elementos antisentido (genética)::ARN antiparalelo::microARN [COMPUESTOS QUÍMICOS Y DROGAS] ,Glucocorticoides - Ús terapèutic - Abstract
Biomarker; Individuals with severe asthma; Oral corticosteroids Biomarcador; Persones amb asma greu; Corticosteroides orals Biomarcador; Personas con asma grave; Corticosteroides orales Nowadays, microRNAs (miRNAs) are increasingly used as biomarkers due to their potential contribution to the diagnosis and targeted treatment of a range of diseases. The aim of the study was to analyze the miRNA expression profiles in serum and lung tissue from patients with severe asthma treated with oral corticosteroids (OCS) and those without OCS treatment. For this purpose, serum and lung tissue miRNAs of OCS and non-OCS asthmatic individuals were evaluated by miRNAs-Seq, and subsequently miRNA validation was performed using RT-qPCR. Additionally, pathway enrichment analysis of deregulated miRNAs was conducted. We observed altered expression by the next-generation sequencing (NGS) of 11 miRNAs in serum, of which five (hsa-miR-148b-3p, hsa-miR-221-5p, hsa-miR-618, hsa-miR-941, and hsa-miR-769-5p) were validated by RT-qPCR, and three miRNAs in lung tissue (hsa-miR-144-3p, hsa-miR-144-5p, and hsa-miR-451a). The best multivariate logistic regression model to differentiate individuals with severe asthma, treated and untreated with OCS, was to combine the serum miRNAs hsa-miR-221-5p and hsa-miR-769-5p. Expression of hsa-miR-148b-3p and hsa-miR-221-5p correlated with FEV1/FVC (%) and these altered miRNAs act in key signaling pathways for asthma disease and the regulated expression of some genes (FOXO3, PTEN, and MAPK3) involved in these pathways. In conclusion, there are miRNA profiles differentially expressed in OCS-treated individuals with asthma and could be used as biomarkers of OCS treatment. This work was supported by ISCIII—Instituto de Salud Carlos III, FIS (Fondo de Investigación Sanitaria—Spanish Health Research Fund) grants PI18/00167, PI21/00896, and FI19/00067; Ciber de Enfermedades Respiratorias (CIBERES); RTC-2017-6501-1 (Ministerio de Ciencia, Innovación y Universidades), a Carlos III Institute of Health Initiative; and FEDER funds (Fondo Europeo de Desarrollo Regional).
- Published
- 2023
32. Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation.
- Author
-
Gil-Martínez M, Rodrigo-Muñoz JM, Lorente-Sorolla C, de Castro ZG, Mínguez P, Cañas JA, Valverde-Monge M, Bernaola J, Pinillos-Robles EJ, Betancor D, Fernández-Nieto M, Sastre J, Rodríguez-Nieto MJ, and Del Pozo V
- Subjects
- Humans, Leukocyte Count, Basophils drug effects, Basophils immunology, Basophils metabolism, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized pharmacology, Cell Degranulation drug effects
- Published
- 2024
- Full Text
- View/download PDF
33. Eosinophil-derived extracellular vesicles: isolation and classification techniques and implications for disease pathophysiology.
- Author
-
Rodrigo-Muñoz JM, Gil-Martínez M, Naharro-González S, and Del Pozo V
- Subjects
- Humans, Animals, Asthma immunology, Asthma pathology, Asthma metabolism, Eosinophils immunology, Eosinophils metabolism, Extracellular Vesicles metabolism, Extracellular Vesicles immunology
- Abstract
Eosinophils are leukocytes characterized by their ability to release granule content that is highly rich in enzymes and proteins. Besides the antihelminthic, bactericidal, and antiviral properties of eosinophils and their secretory granules, these also play a prominent role in the pathophysiology of diseases such as asthma, eosinophilic esophagitis, and other hypereosinophilic conditions by causing tissue damage and airway hyperresponsiveness. Although this cell was first recognized mainly for its capacity to release granule content, nowadays other capabilities such as cytokine secretion have been linked to its physiology, and research has found that eosinophils are not only involved in innate immunity, but also as orchestrators of immune responses. Nearly 10 yr ago, eosinophil-derived extracellular vesicles (EVs) were first described; since then, the EV field has grown exponentially, revealing their vital roles in intracellular communication. In this review, we synthesize current knowledge on eosinophil-derived EVs, beginning with a description of what they are and what makes them important regulators of disease, followed by an account of the methodologies used to isolate and characterize EVs. We also summarize current understanding of eosinophil-derived vesicles functionality, especially in asthma, the disease in which eosinophil-derived EVs have been most widely studied, describing how they modulate the role of eosinophils themselves (through autocrine signaling) and the way they affect airway structural cells and airway remodeling. Deeper understanding of this cell type could lead to novel research in eosinophil biology, its role in other diseases, and possible use of eosinophil-derived EVs as therapeutic targets., Competing Interests: Conflict of interest statement. J.M.R.-M. reports receiving payments for lectures and educational events from AstraZeneca and GSK. V.d.P. has received honoraria (advisory board, speaker) and/or institutional grant/research support from AstraZeneca and GSK and unpaid Leadership or fiduciary role in committees of the EAACI. All other authors declare no conflicts of interest., (© The Author(s) 2024. Published by Oxford University Press on behalf of Society for Leukocyte Biology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
34. Sputum Proteome Reveals Differences Between Eosinophilic and Non-eosinophilic Asthma Phenotypes.
- Author
-
Gil-Martínez M, Rodrigo-Muñoz JM, Antonio Cañas J, Sastre J, Rodríguez-Nieto MJ, and Del Pozo V
- Published
- 2024
- Full Text
- View/download PDF
35. Single-cell RNA sequencing of human blood eosinophils reveals plasticity and absence of canonical cell subsets.
- Author
-
Rodrigo-Muñoz JM, Naharro-González S, Callejas S, Relaño-Ruperez C, Torroja C, Benguria A, Lorente-Sorolla C, Gil-Martínez M, García de Castro Z, Cañas JA, Valverde-Monge M, Bernaola J, Pinillos-Robles EJ, Betancor D, Fernández-Nieto M, Dopazo A, Sánchez-Cabo F, Sánchez-Pernaute O, Rodríguez-Nieto MJ, Sastre J, and Del Pozo V
- Published
- 2024
- Full Text
- View/download PDF
36. Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab.
- Author
-
Almuiña-Varela P, García-Quintanilla L, Rodríguez-Cid MJ, Gil-Martínez M, Abraldes MJ, Gómez-Ulla F, Estany-Gestal A, Alcántara-Espinosa JM, Fernández-Rodríguez M, and Fernández-Ferreiro A
- Abstract
Our objective was to evaluate changes in patient-reported outcome measures using the NEI-VFQ 25 questionnaire during a treat and extend regimen in naive neovascular Age-Related Macular Degeneration patients, and its correlation with anatomical and functional data. We conducted a prospective observational study. Patients underwent a treat and extend regimen with intravitreal ranibizumab for neovascular Age-Related Macular Degeneration. Initial response was evaluated at 4th month, and subsequently in every follow-up visit. If a clinical response was achieved, the injection interval was extended in two-week increments, up to a maximum of 12 weeks. Quality of life was assessed using the NEI-VFQ 25 questionnaire at baseline, 4th months, and 12th months. Patients were categorized as good or poor responders based on Best corrected visual acuity, central foveal thickness, intraretinal fluid, or subretinal fluid. Treatment with ranibizumab led to a significant improvement in quality of life, with a mean increase in NEI-VFQ 25 score of 4.27 points in the 12th month. No significant differences in improvement were observed between good and poor responders. Quality of life scores in neovascular Age-Related Macular Degeneration patients improved with intravitreal treatment regardless of the clinical response. The early response following the loading phase could indicate better quality of life after one year of treatment, with Best corrected visual acuity being the clinical parameter with the greatest influence on quality of life.
- Published
- 2024
- Full Text
- View/download PDF
37. Moderate-High Blood Eosinophilia Is Associated with Increased Hospitalization and Other Asthma Comorbidities.
- Author
-
Naharro-González S, Lorente-Sorolla C, Rodrigo-Muñoz JM, Valverde-Monge M, Pinillos-Robles EJ, Betancor D, Fernández-Nieto M, Sánchez-Mellado D, Gil-Martínez M, Santillán-Coello JM, Villacampa-Aubá JM, Mahillo-Fernandez I, Herrero-González A, Perez-González A, Rodríguez-Nieto MJ, and Del Pozo V
- Subjects
- Humans, Animals, Retrospective Studies, Hospitalization, Asthma complications, Asthma epidemiology, Hypertension, Mustelidae, Pulmonary Eosinophilia, Dyslipidemias epidemiology, Pulmonary Disease, Chronic Obstructive epidemiology
- Abstract
(1) Background: Eosinophilia has traditionally been linked to eosinophilic asthma, for which it is the gold-standard prognostic biomarker. However, the association between eosinophilia and the presence of other diseases and comorbidities is yet unclear. (2) Methods: For this retrospective study, we reviewed the electronic medical records of 49,909 subjects with blood eosinophilia to gather data on the presence of asthma, COPD, sleep apnea, tuberculosis, dyslipidemia, hypertension, and other cardiovascular diseases and severe CRSwNP among these subjects. Demographic features including age, sex, and smoking habits were collected, as well as the number of hospitalizations and emergency department visits. T-tests, ANOVA, Fisher test, and logistic regression models were used. (3) Results: For all age groups studied, eosinophilia was significantly more prevalent among asthmatic subjects than nonasthmatics, especially in patients also presenting CRSwNP, hypertension, and dyslipidemia. The likelihood of developing asthma, COPD, and CRSwNP, and hospitalization, was increased when BEC was above 600 eosinophils/μL. The association between asthma, CRSwNP, and BEC was corroborated by multiple logistic regressions models. (4) Conclusions: We demonstrated the association of having over 600 blood eosinophils/μL with a higher number of hospitalizations and comorbidities (CRSwNP and COPD), which proves that BEC is a highly useful parameter to consider in subjects who present blood eosinophilia.
- Published
- 2024
- Full Text
- View/download PDF
38. The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration.
- Author
-
García-Quintanilla L, Almuiña-Varela P, Rodríguez-Cid MJ, Gil-Martínez M, Abraldes MJ, Gómez-Ulla F, González-Barcia M, Mondelo-García C, Estany-Gestal A, Otero-Espinar FJ, Fernández-Rodríguez M, and Fernández-Ferreiro A
- Abstract
Anti-vascular endothelial growth factor drugs keep being the main therapy for neovascular age-related macular degeneration (AMD). Possible predictive parameters (demographic, biochemical and/or inflammatory) could anticipate short-term treatment response with ranibizumab. 46 treatment-naive patients were included in a prospective observational study. They underwent three monthly injections of intravitreal ranibizumab for neovascular AMD and the clinical examination was made at baseline and one month after the third injection. Demographic characteristics, co-morbidities and concomitant treatments were recorded at the baseline visit. Biochemical parameters, complete blood count and inflammation biomarkers were also measured at these times. Uric Acid was found to be statistically significant with a one-point difference between good and poor responders in both basal and treated patients, but only in basal parameters was statistical significance reached ( p = 0.007 vs. p = 0.071 in treated patients). Cholesterol and inflammatory parameters such as white blood cell count and neutrophils were significantly reduced over time when treated with intravitreal ranibizumab. On the other hand, women seemed to have a worse prognosis for short-term response to intravitreal ranibizumab treatment. Uric acid may help identify possible non-responders before initial treatment with ranibizumab, and cholesterol and white blood cells could be good candidates to monitor short-term response to ranibizumab treatment.
- Published
- 2024
- Full Text
- View/download PDF
39. Obese Asthma Phenotype Is Associated with hsa-miR-26a-1-3p and hsa-miR-376a-3p Modulating the IGF Axis.
- Author
-
Gil-Martínez M, Lorente-Sorolla C, Rodrigo-Muñoz JM, Naharro S, García-de Castro Z, Sastre J, Valverde-Monge M, Quirce S, Caballero ML, Olaguibel JM, and Del Pozo V
- Subjects
- Humans, Biomarkers, Insulin-Like Growth Factor Binding Protein 3 genetics, Phenotype, Quality of Life, Asthma complications, Asthma genetics, MicroRNAs genetics, MicroRNAs metabolism, Obesity complications, Obesity genetics
- Abstract
Clarifying inflammatory processes and categorising asthma into phenotypes and endotypes improves asthma management. Obesity worsens severe asthma and reduces quality of life, although its specific molecular impact remains unclear. We previously demonstrated that hsa-miR-26a-1-3p and hsa-miR-376a-3p, biomarkers related to an inflammatory profile, discriminate eosinophilic from non-eosinophilic asthmatics. We aimed to study hsa-miR-26a-1-3p, hsa-miR-376a-3p, and their target genes in asthmatic subjects with or without obesity to find biomarkers and comprehend obese asthma mechanisms. Lung tissue samples were obtained from asthmatic patients (n = 16) and healthy subjects (n = 20). We measured miRNA expression using RT-qPCR and protein levels (IGF axis) by ELISA in confirmation samples from eosinophilic (n = 38) and non-eosinophilic (n = 39) obese (n = 26) and non-obese (n = 51) asthma patients. Asthmatic lungs showed higher hsa-miR-26a-1-3p and hsa-miR-376a-3p expression than healthy lungs. A study of seven genes regulated by these miRNAs revealed differential expression of IGFBP3 between asthma patients and healthy individuals. In obese asthma patients, we found higher hsa-miR-26a-1-3p and IGF-1R values and lower values for hsa-miR-376a-3p and IGFBP-3. Hsa-miR-26a-1-3p and IGFBP-3 were directly and inversely correlated with body mass index, respectively. Hsa-miR-26a-1-3p and hsa-miR-376a-3p could be used as biomarkers to phenotype patients with eosinophilic and non-eosinophilic asthma in relation to comorbid obesity.
- Published
- 2023
- Full Text
- View/download PDF
40. Advances and Highlights of miRNAs in Asthma: Biomarkers for Diagnosis and Treatment.
- Author
-
Gil-Martínez M, Lorente-Sorolla C, Naharro S, Rodrigo-Muñoz JM, and Del Pozo V
- Subjects
- Humans, Epigenesis, Genetic, Quality of Life, Biomarkers, MicroRNAs genetics, Asthma diagnosis, Asthma drug therapy, Asthma genetics
- Abstract
Asthma is a heterogeneous inflammatory disease of the airways that causes breathing difficulties, episodes of cough and wheezing, and in more severe cases can greatly diminish quality of life. Epigenetic regulation, including post-transcriptional mediation of microRNAs (miRNAs), is one of the mechanisms behind the development of the range of asthma phenotypes and endotypes. As in every other immune-mediated disease, miRNAs regulate the behavior of cells that shape the airway structure as well as those in charge of the defense mechanisms in the bronchi and lungs, controlling cell survival, growth, proliferation, and the ability of cells to synthesize and secrete chemokines and immune mediators. More importantly, miRNAs are molecules with chemical and biological properties that make them appropriate biomarkers for disease, enabling stratification of patients for optimal drug selection and thereby simplifying clinical management and reducing both the economic burden and need for critical care associated with the disease. In this review, we summarize the roles of miRNAs in asthma and describe how they regulate the mechanisms of the disease. We further describe the current state of miRNAs as biomarkers for asthma phenotyping, endotyping, and treatment selection.
- Published
- 2023
- Full Text
- View/download PDF
41. Analysis of Differentially Expressed MicroRNAs in Serum and Lung Tissues from Individuals with Severe Asthma Treated with Oral Glucocorticoids.
- Author
-
Gil-Martínez M, Lorente-Sorolla C, Rodrigo-Muñoz JM, Lendínez MÁ, Núñez-Moreno G, de la Fuente L, Mínguez P, Mahíllo-Fernández I, Sastre J, Valverde-Monge M, Quirce S, Caballero ML, González-Barcala FJ, Arismendi E, Bobolea I, Valero A, Muñoz X, Cruz MJ, Martínez-Rivera C, Plaza V, Olaguibel JM, and Del Pozo V
- Subjects
- Humans, Glucocorticoids therapeutic use, Lung metabolism, Biomarkers, MicroRNAs metabolism, Asthma drug therapy, Asthma genetics
- Abstract
Nowadays, microRNAs (miRNAs) are increasingly used as biomarkers due to their potential contribution to the diagnosis and targeted treatment of a range of diseases. The aim of the study was to analyze the miRNA expression profiles in serum and lung tissue from patients with severe asthma treated with oral corticosteroids (OCS) and those without OCS treatment. For this purpose, serum and lung tissue miRNAs of OCS and non-OCS asthmatic individuals were evaluated by miRNAs-Seq, and subsequently miRNA validation was performed using RT-qPCR. Additionally, pathway enrichment analysis of deregulated miRNAs was conducted. We observed altered expression by the next-generation sequencing (NGS) of 11 miRNAs in serum, of which five (hsa-miR-148b-3p, hsa-miR-221-5p, hsa-miR-618, hsa-miR-941, and hsa-miR-769-5p) were validated by RT-qPCR, and three miRNAs in lung tissue (hsa-miR-144-3p, hsa-miR-144-5p, and hsa-miR-451a). The best multivariate logistic regression model to differentiate individuals with severe asthma, treated and untreated with OCS, was to combine the serum miRNAs hsa-miR-221-5p and hsa-miR-769-5p. Expression of hsa-miR-148b-3p and hsa-miR-221-5p correlated with FEV
1 /FVC (%) and these altered miRNAs act in key signaling pathways for asthma disease and the regulated expression of some genes ( FOXO3 , PTEN , and MAPK3 ) involved in these pathways. In conclusion, there are miRNA profiles differentially expressed in OCS-treated individuals with asthma and could be used as biomarkers of OCS treatment.- Published
- 2023
- Full Text
- View/download PDF
42. Filaggrin and cytokines in respiratory samples of preterm infants at risk for respiratory viral infection.
- Author
-
Rodrigo-Muñoz JM, Sastre B, Sánchez-García L, García-García ML, Gonzalez-Carrasco E, Fabra C, Gil-Martínez M, Lorente-Sorolla C, García-Latorre R, Alcolea S, Casas I, Calvo C, and Del Pozo V
- Subjects
- Humans, Infant, Newborn, Infant, Premature, Intensive Care Units, Neonatal, Cytokines metabolism, Virus Diseases metabolism, Filaggrin Proteins metabolism, Respiratory Tract Diseases virology
- Abstract
Respiratory viral infections (RVIs) are frequent in preterm infants possibly inducing long-term impact on respiratory morbidity. Immune response and respiratory barriers are key defense elements against viral insults in premature infants admitted to Neonatal Intensive Care Units (NICUs). Our main goals were to describe the local immune response in respiratory secretions of preterm infants with RVIs during NICU admission and to evaluate the expression and synthesis of lung barrier regulators, both in respiratory samples and in vitro models. Samples from preterm infants that went on to develop RVIs had lower filaggrin gene and protein levels at a cellular level were compared to never-infected neonates (controls). Filaggrin, MIP-1α/CCL3 and MCP-1 levels were higher in pre-infection supernatants compared to controls. Filaggrin, HIF-1α, VEGF, RANTES/CCL5, IL-17A, IL-1β, MIP-1α and MIP-1β/CCL5 levels were higher during and after infection. ROC curve and logistic regression analysis shows that these molecules could be used as infection risk biomarkers. Small airway epithelial cells stimulated by poly:IC presented reduced filaggrin gene expression and increased levels in supernatant. We conclude that filaggrin gene and protein dysregulation is a risk factor of RVI in newborns admitted at the NICU., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
43. Recent Advances in Proteomics-Based Approaches to Studying Age-Related Macular Degeneration: A Systematic Review.
- Author
-
García-Quintanilla L, Rodríguez-Martínez L, Bandín-Vilar E, Gil-Martínez M, González-Barcia M, Mondelo-García C, Fernández-Ferreiro A, and Mateos J
- Subjects
- Aged, Humans, Angiogenesis Inhibitors therapeutic use, Visual Acuity, Proteomics, Wet Macular Degeneration drug therapy
- Abstract
Age-related macular degeneration (AMD) is a common ocular disease characterized by degeneration of the central area of the retina in the elderly population. Progression and response to treatment are influenced by genetic and non-genetic factors. Proteomics is a powerful tool to study, at the molecular level, the mechanisms underlying the progression of the disease, to identify new therapeutic targets and to establish biomarkers to monitor progression and treatment effectiveness. In this work, we systematically review the use of proteomics-based approaches for the study of the molecular mechanisms underlying the development of AMD, as well as the progression of the disease and on-treatment patient monitoring. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) reporting guidelines were followed. Proteomic approaches have identified key players in the onset of the disease, such as complement components and proteins involved in lipid metabolism and oxidative stress, but also in the progression to advanced stages, including factors related to extracellular matrix integrity and angiogenesis. Although anti-vascular endothelial growth factor (anti-VEGF)-based therapy has been crucial in the treatment of neovascular AMD, it is necessary to deepen our understanding of the underlying disease mechanisms to move forward to next-generation therapies for later-stage forms of this multifactorial disease.
- Published
- 2022
- Full Text
- View/download PDF
44. Reduced miR-146a-5p Is a Biomarker of Infant Respiratory Diseases Contributing to Immune Dysregulation in Small Airway Epithelial Cells.
- Author
-
Rodrigo-Muñoz JM, Gil-Martínez M, Lorente-Sorolla C, Sastre B, García-García ML, Calvo C, Casas I, and Del Pozo V
- Subjects
- Biomarkers metabolism, Cyclooxygenase 2, Epithelial Cells immunology, Epithelial Cells metabolism, Humans, Respiratory Distress Syndrome diagnosis, Respiratory Distress Syndrome metabolism, Respiratory Sounds, Bronchiolitis diagnosis, Bronchiolitis metabolism, Epigenesis, Genetic, MicroRNAs genetics, MicroRNAs metabolism
- Abstract
Respiratory diseases such as bronchiolitis, and those with wheezing episodes, are highly important during infancy due to their potential chronicity. Immune response dysregulation is critical in perpetuating lung damage. Epigenetic modifications including microRNA (miRNA) post-transcriptional regulation are among the factors involved in alleviating inflammation. We evaluated the expression of miR-146a-5p, a previously described negative regulator of immunity, in infants with respiratory diseases, in order to study epigenetic regulation of the immune response. Nasopharyngeal aspirate (NPA) was obtained from infants with bronchiolitis (ongoing and post-disease) or with wheezing episodes in addition to healthy controls. Virus presence was determined by nested PCR, while miRNA and gene expression were studied in cells from NPAs using qPCR. Healthy small airway epithelial cells (SAECs) were used as an in vitro model. We observe a reduction in miR-146a-5p expression in infants with either of the two diseases compared to controls, suggesting the potential of this miRNA as a disease biomarker. Post-bronchiolitis, miR-146a-5p expression increases, though without reaching levels of healthy controls. MiR-146a-5p expression correlates inversely with the immune-related gene PTGS2 , while its expression correlates directly with TSLP . When heathy donor SAECs are stimulated by poly:IC, we observe an increase in miR-146a-5p, with wounds having a synergistic effect. In conclusion, infants with respiratory diseases present reduced miR-146a-5p expression, possibly affecting immune dysregulation.
- Published
- 2022
- Full Text
- View/download PDF
45. miR-144-3p Is a Biomarker Related to Severe Corticosteroid-Dependent Asthma.
- Author
-
Rodrigo-Muñoz JM, Gil-Martínez M, Lorente-Sorolla C, García-Latorre R, Valverde-Monge M, Quirce S, Sastre J, and Del Pozo V
- Subjects
- Adrenal Cortex Hormones therapeutic use, Biomarkers, Humans, Asthma diagnosis, Asthma drug therapy, Asthma genetics, Eosinophilia, MicroRNAs metabolism
- Abstract
MicroRNAs are non-coding molecules that act both as regulators of the epigenetic landscape and as biomarkers for diseases, including asthma. In the era of personalized medicine, there is a need for novel disease-associated biomarkers that can help in classifying diseases into phenotypes for treatment selection. Currently, severe eosinophilic asthma is one of the most widely studied phenotypes in clinical practice, as many patients require higher and higher doses of corticosteroids, which in some cases fail to achieve the desired outcome. Such patients may only benefit from alternative drugs such as biologics, for which novel biomarkers are necessary. The objective of the study was to study the expression of miR-144-3p in order to discover its possible use as a diagnostic biomarker for severe asthma. For this purpose, miR-144-3p was evaluated in airway biopsies and serum from asthmatics and healthy individuals. mRNA was studied in asthmatic biopsies and smooth muscle cells transfected with miR-144-3p mimic. An in silico regulation of miR-144-3p was performed using miRSystem, miRDB, STRING, and ShinyGO for pathway analysis. From our experimental procedures, we found that miR-144-3p is a biomarker associated with asthma severity and corticosteroid treatment. MiR-144-3p is increased in asthmatic lungs, and its presence correlates directly with blood eosinophilia and with the expression of genes involved in asthma pathophysiology in the airways. When studied in serum, this miRNA was increased in severe asthmatics and associated with higher doses of corticosteroids, thereby making it a potential biomarker for severe asthma previously treated with higher doses of corticosteroids. Thus, we can conclude that miR-144-3p is associated with severe diseases in both the airways and serum of asthmatics, and this association is related to corticosteroid treatment., Competing Interests: S.Q. reports personal fees from AstraZeneca, Novartis, Sanofi, Boehringer Ingelheim, Teva, ALK, Mundipharma, GSK, Chiesi, and personal fees from Leti, outside the submitted work. J.S. reports having served as a consultant to Thermofisher, MEDA, Novartis, Sanofi, Leti, Faes Farma, Mundipharma, and GSK; having been paid lecture fees by Novartis, GSK, Stallergenes, Leti, and Faes Pharma; as well as having received grant support for research from Thermofisher, Sanofi, and ALK. V.d.P reports having served as a consultant to Astra Zeneca and GSK and having been paid lecture fees by both. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Rodrigo-Muñoz, Gil-Martínez, Lorente-Sorolla, García-Latorre, Valverde-Monge, Quirce, Sastre and del Pozo.)
- Published
- 2022
- Full Text
- View/download PDF
46. Role of miR-185-5p as modulator of periostin synthesis and smooth muscle contraction in asthma.
- Author
-
Rodrigo-Muñoz JM, Cañas JA, Sastre B, Gil-Martínez M, García Latorre R, Sastre J, and Del Pozo V
- Subjects
- Airway Remodeling genetics, Calcium metabolism, Cell Proliferation genetics, Humans, Muscle Contraction genetics, Myocytes, Smooth Muscle metabolism, Asthma metabolism, MicroRNAs genetics, MicroRNAs metabolism
- Abstract
Asthma is a chronic respiratory disease produced by an aberrant immune response that originates with breathing difficulties and cough, through airway remodeling. The above pathophysiological events of asthma emerge the regulators of effectors, like epigenetics, which include microRNAs (miRNAs) who perform post-transcriptional regulation, controlling diverse pathways in respiratory diseases. The objective of the study was to determine how miR-185-5p regulates the secretion of periostin by airway structural cells, and smooth muscle cells contraction, both related to airway remodeling in asthma. We used miR-185-5p mimic and inhibitors in bronchial smooth muscle cells (BSMCs) and small airway epithelial cells (SAECs) from healthy subjects. Gene expression and protein levels of periostin (POSTN), CDC42, and RHOA were analyzed by RT-PCR and ELISA/Western blot, respectively. BSMC contractility was analyzed using cell-embedded collagen gels and measurement of intracellular calcium was performed using Fura-2. Additionally, miR-185-5p and periostin expression were evaluated in sputum from healthy and asthmatics. From these experiments, we observed that miR-185-5p modulation regulates periostin mRNA and protein in BSMCs and SAECs. A tendency for diminished miR-185-5p expression and higher periostin levels was seen in sputum cells from asthmatics compared to healthy, with an inverse correlation observed between POSTN and miR-185-5p. Inhibition of miR-185-5p produced higher BSMCs contraction induced by histamine. Calcium mobilization was not modified by miR-185-5p, showing that miR-185-5p role in BSMC contractility is performed by regulating CDC42 and RhoA pro-contractile factors instead. In conclusion, miR-185-5p is a modulator of periostin secretion by airway structural cells and of smooth muscle contraction, which can be related to asthma pathophysiology, and thus, might be a promising therapeutic target., (© 2021 The Authors. Journal of Cellular Physiology published by Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
47. Current Situation and Challenges in Vitreous Substitutes.
- Author
-
Mondelo-García C, Bandín-Vilar E, García-Quintanilla L, Castro-Balado A, Del Amo EM, Gil-Martínez M, Blanco-Teijeiro MJ, González-Barcia M, Zarra-Ferro I, Fernández-Ferreiro A, and Otero-Espinar FJ
- Subjects
- Hydrogels therapeutic use, Biocompatible Materials therapeutic use, Vitreous Body
- Abstract
Vitreo-retinal disorders constitute a significant portion of treatable ocular diseases. These pathologies often require vitreo-retinal surgery and, as a consequence, the use of vitreous substitutes. Nowadays, the vitreous substitutes that are used in clinical practice are mainly divided into gases (air, SF
6 , C2 F6 , C3 F8 ) and liquids (perfluorocarbon liquids, silicone oils, and heavy silicone oils). There are specific advantages and drawbacks to each of these, which determine their clinical indications. However, developing the ideal biomaterial for vitreous substitution continues to be one of the most important challenges in ophthalmology, and a multidisciplinary approach is required. In this sense, recent research has focused on the development of biocompatible, biodegradable, and injectable hydrogels (natural, synthetic, and smart), which also act as medium and long-term internal tamponade agents. This comprehensive review aims to cover the main characteristics and indications for use of the extensive range of vitreous substitutes that are currently used in clinical practice, before going on to describe the hydrogels that have been developed recently and which have emerged as promising biomaterials for vitreous substitution., (© 2021 The Authors. Macromolecular Bioscience published by Wiley-VCH GmbH.)- Published
- 2021
- Full Text
- View/download PDF
48. Emerging Evidence for Pleiotropism of Eosinophils.
- Author
-
Rodrigo-Muñoz JM, Gil-Martínez M, Sastre B, and Del Pozo V
- Subjects
- Antibodies, Monoclonal therapeutic use, Asthma drug therapy, Asthma immunology, Asthma pathology, COVID-19 immunology, COVID-19 pathology, COVID-19 virology, Eosinophilic Esophagitis drug therapy, Eosinophilic Esophagitis immunology, Eosinophilic Esophagitis pathology, Eosinophils cytology, Eosinophils immunology, Exosomes metabolism, Extracellular Traps metabolism, Humans, Plasma Cells cytology, Plasma Cells metabolism, SARS-CoV-2 isolation & purification, Eosinophils physiology
- Abstract
Eosinophils are complex granulocytes with the capacity to react upon diverse stimuli due to their numerous and variable surface receptors, which allows them to respond in very different manners. Traditionally believed to be only part of parasitic and allergic/asthmatic immune responses, as scientific studies arise, the paradigm about these cells is continuously changing, adding layers of complexity to their roles in homeostasis and disease. Developing principally in the bone marrow by the action of IL-5 and granulocyte macrophage colony-stimulating factor GM-CSF, eosinophils migrate from the blood to very different organs, performing multiple functions in tissue homeostasis as in the gastrointestinal tract, thymus, uterus, mammary glands, liver, and skeletal muscle. In organs such as the lungs and gastrointestinal tract, eosinophils are able to act as immune regulatory cells and also to perform direct actions against parasites, and bacteria, where novel mechanisms of immune defense as extracellular DNA traps are key factors. Besides, eosinophils, are of importance in an effective response against viral pathogens by their nuclease enzymatic activity and have been lately described as involved in severe acute respiratory syndrome coronavirus SARS-CoV-2 immunity. The pleiotropic role of eosinophils is sustained because eosinophils can be also detrimental to human physiology, for example, in diseases like allergies, asthma, and eosinophilic esophagitis, where exosomes can be significant pathophysiologic units. These eosinophilic pathologies, require specific treatments by eosinophils control, such as new monoclonal antibodies like mepolizumab, reslizumab, and benralizumab. In this review, we describe the roles of eosinophils as effectors and regulatory cells and their involvement in pathological disorders and treatment.
- Published
- 2021
- Full Text
- View/download PDF
49. Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma.
- Author
-
Cañas JA, Valverde-Monge M, Rodrigo-Muñoz JM, Sastre B, Gil-Martínez M, García-Latorre R, Rial MJ, Gómez-Cardeñosa A, Fernández-Nieto M, Pinillos-Robles EJ, Rodríguez-Nieto MJ, González-Mangado N, Sastre J, and Pozo VD
- Abstract
Severe eosinophilic asthma poses a serious health and economic problem, so new therapy approaches have been developed to control it, including biological drugs such as benralizumab, which is a monoclonal antibody that binds to IL-5 receptor alpha subunit and depletes peripheral blood eosinophils rapidly. Biomarkers that predict the response to this drug are needed so that microRNAs (miRNAs) can be useful tools. This study was performed with fifteen severe eosinophilic asthmatic patients treated with benralizumab, and serum miRNAs were evaluated before and after treatment by semi-quantitative PCR (qPCR). Patients showed a clinical improvement after benralizumab administration. Additionally, deregulation of miR-1246, miR-5100 and miR-338-3p was observed in severe asthmatic patients after eight weeks of therapy, and a correlation was found between miR-1246 and eosinophil counts, including a number of exacerbations per year in these severe asthmatics. In silico pathway analysis revealed that these three miRNAs are regulators of the MAPK signaling pathway, regulating target genes implicated in asthma such as NFKB2 , NFATC3 , DUSP1 , DUSP2 , DUSP5 and DUSP16 . In this study, we observed an altered expression of miR-1246, miR-5100 and miR-338-3p after eight weeks of benralizumab administration, which could be used as early response markers.
- Published
- 2021
- Full Text
- View/download PDF
50. Exosomes: A Key Piece in Asthmatic Inflammation.
- Author
-
Cañas JA, Rodrigo-Muñoz JM, Gil-Martínez M, Sastre B, and del Pozo V
- Subjects
- Animals, Asthma pathology, Cell Communication physiology, Cell-Derived Microparticles metabolism, Exosomes pathology, Humans, Inflammation pathology, Secretory Vesicles pathology, Secretory Vesicles physiology, Asthma etiology, Exosomes physiology, Inflammation etiology
- Abstract
Asthma is a chronic disease of the airways that has an important inflammatory component. Multiple cells are implicated in asthma pathogenesis (lymphocytes, eosinophils, mast cells, basophils, neutrophils), releasing a wide variety of cytokines. These cells can exert their inflammatory functions throughout extracellular vesicles (EVs), which are small vesicles released by donor cells into the extracellular microenvironment that can be taken up by recipient cells. Depending on their size, EVs can be classified as microvesicles, exosomes, or apoptotic bodies. EVs are heterogeneous spherical structures secreted by almost all cell types. One of their main functions is to act as transporters of a wide range of molecules, such as proteins, lipids, and microRNAs (miRNAs), which are single-stranded RNAs of approximately 22 nucleotides in length. Therefore, exosomes could influence several physiological and pathological processes, including those involved in asthma. They can be detected in multiple cell types and biofluids, providing a wealth of information about the processes that take account in a pathological scenario. This review thus summarizes the most recent insights concerning the role of exosomes from different sources (several cell populations and biofluids) in one of the most prevalent respiratory diseases, asthma.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.